Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Champions Oncology, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 28 | 29 | +1 |
| Shares | 5.81M | 5.74M | −72.2K (−1.2%) |
| Value | $37.0M | $35.6M | −$1.40M (−3.8%) |
New holders (3)
Institutions that held Champions Oncology, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 3,126 | $19.4K | 0.00% |
| Simplex Trading, LLC | 1,064 | $6.00K | 0.00% |
| Steward Financial Group LLC | 775 | $4.00K | 0.00% |
Sold out (2)
Institutions that held Champions Oncology, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Susquehanna Fundamental Investments, LLC | 15,449 | $97.2K |
| Globeflex Capital L P | 5,564 | $35.0K |